Relationships between hematological recovery and overall survival in older adults undergoing allogeneic bone marrow transplantation

Internal Medicine

Volumn 44, Issue 1, 2005, Pages 35-40

  Tabata, Masahiko ^a   Kai, Shunro ^a   Satake, Atsushi ^a   Wakae, Takeshi ^a   Toda, Akinari ^a   Chin, Meishu ^a   Nishioka, Keisuke ^a   Tanaka, Hidehisa ^a   Itsukuma, Takeyoshi ^a   Yamaguchi, Masao ^a   Okada, Masaya ^a   Takatsuka, Hiroyuki ^a   Misawa, Mahito ^a   Hara, Hiroshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Bone marrow transplantation; Elderly; Hematological malignancy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; BETA LACTAM ANTIBIOTIC; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLADDER DISEASE; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION CONTROL; LIVER TOXICITY; LUNG TOXICITY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL; RETROSPECTIVE STUDY; STOMATITIS; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT INDICATION;

ADULT; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PLATELET COUNT; RETROSPECTIVE STUDIES;

EID: 13844316591     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.35     Document Type: Article

References (25)

1. Aschan J, Ringden O. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Clin Transplant 8: 258-270, 1994.
2. Horowitz MM, Loberiza FR, Bredeson CN, Rizzo JD, Nugent ML. Transplant registries: Guiding clinical decisions and improving outcomes. Oncology 15: 649-659, 2001.
3. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18: 295-304, 1974.
4. Sullivan KM. Acute and chronic graft versus-host disease in man. Int J Cell Cloning 4: 42-98, 1986.
5. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
6. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Analysis and examples. Br J Cancer 35: 1-39, 1977.
7. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6: 1562-1568, 1988.
8. Klingemann HG, Storb R, Fefer A, et al. Bone marrow transplantation in patients aged 45 years and older. Blood 67: 770-776, 1986.
9. Ringden O, Horowitz MM, Gale RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 270: 57-60, 1993.
10. Cahn JY, Labopin M, Schattenberg A, et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT) Leukemia 11: 416-419, 1997.
11. Ringden O, Remberger M, Mattsson J, et al. Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Bone Marrow Transplant 21: 43-49, 1998.
12. Dominietto A, Raiola AM, Van Lint MT, et al. Factors influencing haematological recovery after allogeneic haematopoietic stem cell transplants: graft versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 112: 219-227, 2001.
13. Nash RA, Gooley T, Davis C, Appelbaum FR. The problem of thrombocytopenia after hematopoietic stem cell transplantation. Stem Cells 14: 261-273, 1996.
14. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stern cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 88: 2794-2800, 1996.
15. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 19: 143-147, 1997.
16. Barge RMY, Brouwer RE, Beersma MFC, et al. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome. Bone Marrow Transplant 27: 1053-1058, 2001.
17. Copelan EA, Kapoor N, Berliner M, Tutschka PJ. Bone marrow transplantation without total-body irradiation in patients aged 40 and older. Transplantation 48: 65-68, 1989.
18. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 18: 273-284, 1994.
19. Wolff SN, Herzig R, Lynch J, et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant 27: 261-268, 2001.
20. Fox N, Priestley G, Papayannopoulou T, Kaushansky K. Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest 110: 389-394, 2002.
21. Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stern cell transplantation from human leukocyte antigen-matched related donors. Blood 97: 3405-3410, 2001.
22. Özcan M, Ustun C, Akcaglayan E, et al. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 27: 499-505, 2001.
23. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrxate. Blood 80: 1838-1845, 1992.
24. Rapoport AP, DiPersio JF, Martin BA, et al. Patients ≥age 40 years undergoing autologous or allogeneic BMT have regime-related mortality rates and event-free survivals comparable to patients
25. Du W, Dansey R, Abella EM, et al. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age - a single institution's experience. Bone Marrow Transplant 21: 1043-1047, 1998.